Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Sexually transmitted infections in young people and factors associated with HIV coinfection: an observational study in a large city.
Sentís A, Martin-Sanchez M, Arando M, Vall M, Barbera MJ, Ocaña I, González Cordón A, Alsina M, Martin-Ezquerra G, Knobel H, Gurguí M, Vives A, Coll J, Caylà JA, Garcia de Olalla P; STI-HIV group of Barcelona. Sentís A, et al. Among authors: knobel h. BMJ Open. 2019 May 5;9(5):e027245. doi: 10.1136/bmjopen-2018-027245. BMJ Open. 2019. PMID: 31061051 Free PMC article.
[Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)].
Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, Pérez-Molina JA; Investigadores del Estudio CUVA. Viciana P, et al. Among authors: knobel h. Enferm Infecc Microbiol Clin. 2008 Mar;26(3):127-34. doi: 10.1157/13116748. Enferm Infecc Microbiol Clin. 2008. PMID: 18358210 Spanish.
Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA; COINS Study Team. Macías J, et al. Among authors: knobel h. HIV Clin Trials. 2012 Mar-Apr;13(2):61-9. doi: 10.1310/hct1302-61. HIV Clin Trials. 2012. PMID: 22510353
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
Blasco AJ, Llibre JM, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA. Blasco AJ, et al. Among authors: knobel h. Enferm Infecc Microbiol Clin. 2013 Nov;31(9):568-78. doi: 10.1016/j.eimc.2013.06.002. Epub 2013 Aug 20. Enferm Infecc Microbiol Clin. 2013. PMID: 23969276 Spanish.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
343 results